Pneumocystis jirovecii colonization in chronic pulmonary disease

Parasite

and C. De La Horra²  E.J. Calderón²  M.T. Martínez-Risquez¹  E. Campano³  N. Respaldiza²  S. Gutiérrez¹ 

[1] Servicio de Medicina Interna Hospital Universitario Virgen del Rocío,Seville,Spain;CIBER en Epidemiología y Salud Pública, Hospital Universitario Virgen del Rocío,Seville,Spain;Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla,Seville,Spain

关键词: chronic pulmonary disease;    colonization;    Pneumocystis jirovecii;   

Others  :  808866
DOI  :  doi:10.1051/parasite/2011182121

 received in 2010-06-30, accepted in 2010-10-31,  发布年份 2011

【 摘 要 】

Pneumocystis jirovecii causes pneumonia in immunosuppressed individuals. However, it has been reported the detection of low levels of Pneumocystis DNA in patients without signs and symptoms of pneumonia, which likely represents colonization. Several studies performed in animals models and in humans have demonstrated that Pneumocystis induces a local and a systemic response in the host. Since P. jirovecii colonization has been found in patients with chronic pulmonary diseases it has been suggested that P. jirovecii may play a role in the physiopathology and progression of those diseases. In this report we revise P. jirovecii colonization in different chronic pulmonary diseases such us, chronic obstructive pulmonary disease, interstitial lung diseases, cystic fibrosis and lung cancer.

【 授权许可】

   
© PRINCEPS Editions, Paris, 2011

【 参考文献 】

• [1]Antunes J., Fernandes A., Borrego L.M., Leiria-Pinto P. & Cavaco J. Cystic fibrosis, atopy, asthma and ABPA. Allergol Immunopathol, 2010, 38, 278–284.
• [2]Benfield T.L., Lundgren B., Shelhamer J.H. & Lundgren J.D. Pneumocystis carinii major surface glycoprotein induces interleukin-8 and monocyte chemoattractant protein-I release from a human alveolar epithelial cell line. European Journal of Clinical Investigation, 1999, 29, 717–22. [PubMed]
• [3]Calderón E.J., Regordan C., Medrano F.J., Ollero M. & Varela J.M. Pneumocystis carinii infection in patients with chronic bronchial disease. Lancet, 1996, 347, 977.
• [4]Calderón E., de la Horra C., Medrano F.J., López-Suárez A., Montes-Cano M.A., Respaldiza N., Elvira-González J., Martín-Juan J., Bascuñana A. & Varela J.M. Pneumocystis jiroveci isolates with dihydropteroate synthase mutations in patients with chronic bronchitis. European Journal of Clinical Microbiology & Infectious Diseases, 2004, 23, 545–549.
• [5]Calderón E.J, Rivero L., Respaldiza N., Morilla R., Montes-Cano M.A., Friaza V., Muñoz-Lobato F., Varela J.M., Medrano F.J. & de la Horra C. Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci. Clinical Infectious Diseases, 2007, 45, e17–e19. [PubMed]
• [6]Calderón E.J. Epidemiology of Pneumocystis infection in Human. Journal de Mycologie Médicale, 2009, 19, 270–275.
• [7]Calderón E.J., Gutiérrez-Rivero S., Durand-Joly I. & Deicas E. Pneumocystis infection in humans: diagnosis and treatment. Expert Review of Anti-infective Therapy, 2010, 8, 259–262. [PubMed]
• [8]Cano S., Capote F., Pereira A., Calderón E. & Castillo J. Pneumocystis carinii pneumonia in patients without predisposing illnesses. Acute episode and follow-up of five cases. Chest, 1993, 104, 376–381. [PubMed]
• [9]Chapman K.R., Mannino D.M., Soriano J.B., Vermeire P.A., Buist A.S., Thun M.J., Connell C., Jemal A., Lee T.A., Miravitlles M., Aldington S. & Beasley R. Epidemiology and costs of chronic obstructive pulmonary disease. European Respiratory Journal, 2006, 27, 188–207.
• [10]Christensen P.J., Preston A.M., Ling T., Du M., Fields W.B., Curtis J.L. & Beck J.M. Pneumocystis murina infection and cigarette smoke exposure interact to cause increased organism burden, development of airspace enlargement, and pulmonary inflammation in mice. Infection and Immunity, 2008, 76, 3481–3490. [PubMed]
• [11]de la Horra C., Varela J.M., Fernández-Alonso J., Medrano F.J., Respaldiza N., Montes-Cano M.A. & Calderón E.J. Association between human-Pneumocystis infection and small-cell lung carcinoma. European Journal of Clinical Investigation, 2004, 34, 229–235. [PubMed]
• [12]du Bois R.M., Goh N., Mcgrath D. & Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? Journal of Internal Medicine, 2003, 253, 4–17. [PubMed]
• [13]Egan J.J., Woodcock A.A. & Stewart J.P. Viruses and idiopathic pulmonary fibrosis. European Respiratory Journal, 1997, 10, 1433–1437.
• [14]Friaza V., de la Horra C., Rodríguez-Domínguez M.J., Martínjuan J., Cantón R., Calderón E.J. & Del Campo R. Metagenomic analysis of bronchoalveolar lavage samples from patients with idiopathic interstitial pneumonia and its antagonic relation with Pneumocystis jirovecii colonization. Journal of Microbiological Methods, 2010, 82, 98–101. [PubMed]
• [15]Gal S.L., Héry-Arnaud G., Ramel S., Virmaux M., Damiani C., Totet A. & Nevez G. Pneumocystis jirovecii and cystic fibrosis in France. Scandinavian Journal of Infectious Diseases, 2010, 42, 225–227. [PubMed]
• [16]Gan W.Q., Man S.F.P., Senthilselvan A. & Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax, 2004, 59, 574–580. [PubMed]
• [17]Krajicek B.J., Limper A.H. & Thomas C.F. Jr. Advances in the biology, pathogenesis and identification of Pneumocystis pneumonia. Current Opinion in Pulmonary Medicine, 2008, 14, 228–234. [PubMed]
• [18]Kuper H., Adami H.O. & Trichopoulos D. Infections as a major preventable cause of human cancer. Journal of Internal Medicine, 2000, 248, 171–183. [PubMed]
• [19]Lebron F., Vassallo R., Puri V. & Limper H. Pneumocystis carinii cell wall β-glucans initiate macrophage inflammatory responses through NFκB activation. The Journal of Biological Chemistry, 2003, 278, 25001–25008. [PubMed]
• [20]Lopez A.D., Shibuya K., Rao C., Mathers C.D., Hansell A.L., Held L.S., Schmid V. & Buist S. Chronic obstructive pulmonary disease: current burden and future projections. European Respirory Journal, 2006, 27, 397–412.
• [21]Lubis N., Baylis D., Short A., Stebbing J., Teague A., Portsmouth S., Bower M., Nelson M. & Gazzard B. Prospective cohort study showing changes in the monthly incidence of Pneumocystis carinii pneumonia. Postgraduate Medical Journal, 2003, 79, 164–166. [PubMed]
• [22]Martín-Juan J., Gómez-Izquierdo L., Lara L., Rodríguezbecerra E., de la Horra C., Montes-Cano M.A., Respaldiza N. & Calderón E. Factores relacionados con la infección por Pneumocystis jirovecii en pacientes con enfermedad pulmonar intersticial difusa. Neumosur, 2008, 20, 65–73.
• [23]Macnee W. Pathogenesis of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society, 2005, 2, 258–266. [PubMed]
• [24]Montes-Cano M.A., de la Horra C., Dapena F.J., Mateos I., Friaza V., Respaldiza N., Muñoz-Lobato F., Medrano F.J., Calderón E.J. & Varela J.M. Dynamic colonisation by different Pneumocystis jirovecii genotypes in cystic fibrosis patients. Clinical Microbiology and Infection, 2007, 13, 1008–1011. [PubMed]
• [25]Morris A., Kingsley L.A., Groner G., Lebedeva I.P., Beard C.B. & Norris K.A. Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men. AIDS, 2004a, 18, 793–798.
• [26]Morris A., Sciurba F.C., Lebedeva I.P., Githaiga A., Elliott W.M., Hogg J.C., Huang L. & Norris K.A. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. American Journal of Respiratory and Critical Care Medicine, 2004b, 170, 408–413. [PubMed]
• [27]Morris A., Sciurba F.C. & Norris K.A. Pneumocystis: a novel pathogen in chronic obstructive pulmonary disease? COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008a, 5, 43–51.
• [28]Morris A., Wei K., Afshar K. & Huang L. Epidemiology and clinical significance of Pneumocystis colonization. The Journal of Infectious Diseases, 2008b, 197, 10–17. [PubMed]
• [29]Nevez G., Magois E., Duwat H., Gouilleux V., Jounieaux V. & Totet A. Apparent absence of Pneumocystis jirovecii in healthy subjects. Clinical Infectious Diseases, 2006, 42, e99–e101.
• [30]Peterson J.C. & Cushion M.T. Pneumocystis: not just pneumonia. Current Opinion in Microbiology, 2005, 8, 393–398. [PubMed]
• [31]Pisani P., Parkin D.M., Muñoz N. & Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiology, Biomarkers & Prevention, 1997, 6, 387–400.
• [32]Prévost M.C., Escamilla R., Aliouat E.M., Ceré N., Coudert P. & Dei-Cas E. Pneumocystosis pathophysiology. FEMS Immunology and Medical Microbiology, 1998, 28, 123–128.
• [33]Respaldiza N., Montes-Cano M.A., Dapena F.J., de la Horra C., Mateos I., Medrano F.J., Calderón E. & Varela J.M. Prevalence of colonisation and genotypic characterisation of Pneumocystis jirovecii among cystic fibrosis patients in Spain. Clinical Microbiology and Infection, 2005, 11, 1012–1015.
• [34]Rice W.R., Singleton F.M., Linke M.J. & Walzer P.D. Regulation of surfactant phosphatidilcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat. The Journal of Clinical Investigation, 1993, 92 (6), 2778–2782. [PubMed]
• [35]Rivero L., de la Horra C., Montes-Cano M.A., Rodríguezherrera A., Respaldiza N., Friaza V., Morilla R., Gutiérrez S., Varela J.M., Medrano F.J. & Calderón E.J. Pneumocystis jirovecii transmission from immunocompetent carriers to infant. Emerging Infectious Diseases, 2008, 14, 1116–1118. [PubMed]
• [36]Rowe S.M., Miller S., Sorscher E.J. Cystic fibrosis. The New England Journal of Medicine, 2005, 352, 1992–2001. [PubMed]
• [37]Shimizu Y., Sunaga N., Dobashi K., Fueki M., Fueki N., Makino S. & Mori M. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infectious Diseases, 2009, 9, 47. [PubMed]
• [38]Sing A., Geiger A.M., Hogardt M. & Heeseman J. Pneumocystis carinii carriage among cystic fibrosis patients, as detected by nested PCR. Journal of Clinical Microbiology, 2001, 39, 2717–2718. [PubMed]
• [39]Sing A., Schmoldt S., Laubender R.P., Heesemann J., Sing D. & Wildner M. Seasonal variation of Pneumocystis jirovecii infection: analysis of underlying climatic factors. Clinical Microbiology and Infection, 2009, 15, 957–960.
• [40]Stein C.R., Poole C., Kazanjian P. & Meshnick S.R. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerging Infectious Diseases, 2004, 10, 1760–1765. [PubMed]
• [41]Thomas C.F. & Limper A.H.. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nature Reviews Microbiology, 2007, 5, 298–308. [PubMed]
• [42]Varela J.M., Regordán C., Medrano F.J., Respaldiza N., de la Horra C., Montes-Cano M.A. & Calderón E.J. Climatic factors and Pneumocystis jirovecii infection in southern Spain. Clinical Microbiology and Infection, 2004, 10, 770–772.
• [43]Vidal S., de la Horra C., Martín J., Montes-Cano M.A., Rodríguez E., Respaldiza N., Rodríguez F., Varela J.M., Medrano F.J. & Calderón E.J. Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clinical Microbiology and Infection, 2006, 12, 231–235. [PubMed]
• [44]Wissmann G., Morilla R., Friaza V., Calderón E. & Varela J.M. El ser humano como reservorio de Pneumocystis. Enfermedades Infecciosas y Microbiología Clínica, 2010, 28, 38–43.